4.7 Review

Nanomedicinal strategies to treat multidrug-resistant tumors: current progress

Journal

NANOMEDICINE
Volume 5, Issue 4, Pages 597-615

Publisher

FUTURE MEDICINE LTD
DOI: 10.2217/NNM.10.35

Keywords

Brij; drug delivery; efflux transporters; lipid formulation; nanoparticle; P-glycoprotein; Pluronic; vitamin E TPGS

Funding

  1. NIH [R01 CA115197]

Ask authors/readers for more resources

Multidrug resistance (MDR) is a major impediment to the success of cancer chemotherapy. P-glycoprotein is an important and the best-known membrane transporter involved in MDR. Several strategies have been used to address MDR, especially P-glycoprotein-mediated drug resistance in tumors. However, clinical success has been limited, largely due to issues regarding lack of efficacy and/or safety. Nanoparticles have shown the ability to target tumors based on their unique physical and biological properties. To date, nanoparticles have been investigated primarily to address P-glycoprotein and the observed improved anticancer efficacy suggests that nanomedicinal strategies provide a new opportunity to overcome MDR. This article focuses on nanotechnology-based formulations and current nanomedicine approaches to address MDR in tumors and discusses the proposed mechanisms of action.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available